SML2807
JP4-039
≥98% (HPLC)
别名:
4-[[(3E,5S)-5-[[(1,1-Dimethylethoxy)carbonyl]amino]-7-methyl-1-oxo-3-octen-1-yl]amino]-2,2,6,6-tetramethyl-1-piperidinyloxy, JP 4-039
InChI
1S/C23H42N3O4/c1-16(2)13-17(25-20(28)30-21(3,4)5)11-10-12-19(27)24-18-14-22(6,7)26(29)23(8,9)15-18/h10-11,16-18H,12-15H2,1-9H3,(H,24,27)(H,25,28)/b11-10+/t17-/m1/s1
InChI key
AJHRJWQXDNEJAG-SXSDINLZSA-N
SMILES string
O=C(C/C=C/[C@@H](NC(OC(C)(C)C)=O)CC(C)C)NC1CC(C)(C)N([O])C(C)(C)C1
assay
≥98% (HPLC)
form
powder
color
faint yellow to dark orange
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
JP4-039 is an electron-/reactive oxygen species (ROS)-scavenging GS-nitroxide composed of 4-amino-TEMPO and a truncated gramicidin S (GS) mitochrondria-targeting sequence. JP4-039 is a superior irradiation mitigator than XJB-5-131 (33% vs. 20% mice survial rate on day 35 with respective compound; 23.6 μmol/kg iv. 24 hr post 9.5 Gy whole body irradiation), while displaying weaker anti-ferroptotic potency (EC50 = 3.58 μM/1.27 μM against 10 μM erastin-/2 μM RSL3-induced HT-1080 ferroptosis vs. 114 nM/68 nM with XJB-5-131) due to lower lipophilicity & mitochondria enrichment. Typical dosing range: 40 nM-10 μM in cultures and 10-20 mg/kg in mice (im., ip., iv.) in vivo.
Mitochondrial-targeted reactive oxygen species (ROS)-scavenging gramicidin S (GS)-nitroxide with in vitro and in vivo efficacy against irradiation-induced damage.
存储类别
11 - Combustible Solids
wgk
WGK 3
Malolan S Rajagopalan et al.
In vivo (Athens, Greece), 23(5), 717-726 (2009-09-26)
It was unknown if a mitochondria-targeted nitroxide (JP4-039) could augment potentially lethal damage repair (PLDR) of cells in quiescence. We evaluated 32D cl 3 murine hematopoietic progenitor cells which were irradiated and then either centrifuged to pellets (to simulate PLDR
Justin Steinman et al.
Radiation research, 189(1), 68-83 (2017-11-16)
The acute lethality of total-body irradiation (TBI) involves damage to multiple organs, including bone marrow and intestine. Ionizing radiation mitigators that are effective when delivered 24 h or later after TBI include the anti-apoptotic drug, JP4-039 and the anti-necroptotic drug
Abhay Gokhale et al.
In vivo (Athens, Greece), 24(4), 377-385 (2010-07-30)
We studied radioprotection and mitigation by mitochondrial-targeted Tempol (GS-nitroxide, JP4-039), in a mouse injury/irradiation model of combined injury (fracture/irradiation). Right hind legs of control C57BL/6NHsd female mice, mice pretreated with MnSOD-PL, JP4-039, or with amifostine were irradiated with single and
Michael W Epperly et al.
In vivo (Athens, Greece), 32(5), 1009-1023 (2018-08-29)
The mitochondrial targeted GS-nitroxide, JP4-039, is an effective total body irradiation (TBI) mitigator when delivered intravenously (IV) up to 72 h after exposure. Effective systemic and localized administration to oral cavity/oropharynx and esophagus has been demonstrated. The objective of the
Mark E Bernard et al.
Radiation research, 176(5), 603-612 (2011-09-24)
Fanconi anemia (FA) is an inherited disorder characterized by defective DNA repair and cellular sensitivity to DNA crosslinking agents. Clinically, FA is associated with high risk for marrow failure, leukemia and head and neck squamous cell carcinoma (HNSCC). Radiosensitivity in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持